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Dear Editor, 
Keratinocyte cancers (KC) are the commonest malignancies in the UK population, with rates increasing 
annually.¹ Nicotinamide (vitamin B3) has recently been reported to reduce the incidence of KC in high-risk 
patients.² It is a precursor of nicotinamide adenine dinucleotide (NAD+) which replenishes cellular energy 
levels and enhances efficient repair of ultraviolet light (UV) induced DNA damage within keratinocytes.3 
Solid organ transplant recipients (OTRs) are at particularly high risk of KC, with 150 times increased risk of 
cutaneous squamous cell carcinoma (cSCC) compared with the immunocompetent general population.4 
Recent randomised controlled trial (RCT) data from Australia suggest that oral nicotinamide reduces cSCC 
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Although trials investigating the role of nicotinamide in OTRs are planned or underway in Australia and 
Canada (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372709; 
https://clinicaltrials.gov/ct2/show/NCT03769285), to date, there have been no trials evaluating the 
chemopreventative role of nicotinamide in a UK OTR population. 
We propose a randomised controlled trial (RCT) comparing nicotinamide versus placebo in risk reduction of 
cSCC in high-risk OTRs in the UK. To explore feasibility of undertaking this RCT we assessed willingness 
of UK clinicians and OTRs to participate and their potential concerns. An electronic Survey MonkeyTM 
questionnaire was sent to Dermatologists and Transplant Units (August 2018 – April 2019). Anonymised 
paper-based surveys were self-completed by OTRs when attending dedicated Transplant Dermatology 
Clinics (January 2019 – May 2019). Data were entered and analysed using Microsoft Excel. 
Clinician survey: 99 clinicians (1 male:1.4 female) from 40 UK National Health Service (NHS) Trusts (in 
England, Scotland, Wales and Northern Ireland) responded (79% consultants: 87% dermatologists, 12% 
transplant physicians; response rate approximately 10%). 38% of respondents reviewed an average of 1-2 
OTR/week, with 50% reviewing > 2 OTRs/week. 67 of 99 replied to questions on systemic 
chemoprevention. 49 of 67 (73%) respondents had initiated systemic chemoprevention, with acitretin the 
most frequent first-line choice (40/67, 60%); 24% (16/67) had used nicotinamide previously. 72 
respondents replied to the question of whether they would be willing to recruit patients to this study; of 
these 59 (82%) would be willing. Specific concerns included optimising the definition of high-risk OTRs in 
order to maximise event rate. 
OTR survey: 271 of 301 OTRs from 11 NHS Trusts (England, Scotland and Wales) responded (response 
rate 90%), 1 male:1.6 female; mean age 57 years (y), range 18 – 83y; mean time from first transplant 14.4 
y (range 0 – 51y). The majority were renal transplant recipients (65%) with 14% lung, 12% heart, 4% liver, 
1% pancreas and 0.4% bowel transplant recipients. 66 (24%) reported a prior cSCC history, with 50% of 
this cohort (n=33) reporting > 5 KC. 6% of respondents had previously received systemic chemoprevention: 
4% (10/271) with acitretin and 3% (7/271) nicotinamide. Topical chemoprevention used at least once 
included 5% 5-fluorouracil cream (15%), 5% imiquimod cream (2%) and diclofenac in hyaluronic acid gel 
(1%). Overall, 71% (193/271) were willing to participate in the proposed trial.  For patients with a past 
history of cSCC, and therefore eligible for recruitment to the proposed RCT, this increased to 85% (56/66). 
Specific concerns raised included the need for additional hospital visits and blood tests and potential 
interactions between nicotinamide and regular medications. 
Skin cancers in OTRs are more frequent and aggressive, with a greater risk of tumour recurrence, local 
invasion and metastasis than in the immunocompetent population.4, 5 This feasibility survey has confirmed 
that the systemic chemoprevention strategy used most frequently in the UK is oral acitretin, a drug with 
significant adverse effects, and that current use of nicotinamide is limited. It is important that 
chemoprevention is safe, inexpensive and has few side effects. Nicotinamide fulfils these criteria and, if 
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acitretin, but could also be used in conjunction with acitretin in the highest-risk patients. These feasibility 
surveys demonstrated support for a UK-based trial amongst both clinicians and in OTRs. Given the low-
cost and low toxicity of oral nicotinamide, confirmation of its efficacy in a UK OTR population has the 
potential to transform chemopreventative practice in this growing high-risk patient population. 
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